Novavax announced it will provide strategic and business updates at the 2024 Jefferies London Healthcare Conference on November 20, 2024. The presentation will cover corporate strategy, operating plans, and future prospects, including updates on partnerships, manufacturing capacity, and product development pipeline.Key focus areas include the company's COVID-19 vaccine production and delivery plans, development of clinical and preclinical product candidates, and financial guidance for 2024-2026. The presentation will also address cost reduction initiatives, existing advanced purchase agreements, and potential sale of the Czech Republic manufacturing facility.The investor presentation materials will be accessible on Novavax's website under "Latest Investor Presentation." The company notes that forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from current expectations.

Novavax announced it will provide strategic and business updates at the 2024 Jefferies London Healthcare Conference on November 20, 2024. The presentation will cover corporate strategy, operating plans, and future prospects, including updates on partnerships, manufacturing capacity, and product development pipeline.Key focus areas include the company's COVID-19 vaccine production and delivery plans, development of clinical and preclinical product candidates, and financial guidance for 2024-2026. The presentation will also address cost reduction initiatives, existing advanced purchase agreements, and potential sale of the Czech Republic manufacturing facility.The investor presentation materials will be accessible on Novavax's website under "Latest Investor Presentation." The company notes that forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from current expectations.